Literature DB >> 11091284

The p53 status in juvenile chronic arthritis and rheumatoid arthritis.

H Taubert1, B Thamm, A Meye, F Bartel, A K Rost, D Heidenreich, V John, J Brandt, M Bache, P Würl, H Schmidt, D Riemann.   

Abstract

The aim of this study was to investigate the p53 status in two autoimmune diseases; juvenile chronic arthritis (JCA) and rheumatoid arthritis (RA). In a PCR-sequencing analysis of exons 4-9 of the p53 gene, no mutation was identified, except for the case of an RA synovectomy sample with two mutations of intron 7. p53 gene polymorphisms for codons 36, 47, and 213 were not detected. Codon 72 polymorphism showed an indication of an increased occurrence of the Pro/Pro allelotype in JCA. Expression of P53 protein was comparable for JCA and RA synovectomy samples. For all RA samples P53 protein was detectable, whereas one sample of a JCA patient failed to express P53 protein.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11091284      PMCID: PMC1905773          DOI: 10.1046/j.1365-2249.2000.01358.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

Review 1.  Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases.

Authors:  P P Tak; N J Zvaifler; D R Green; G S Firestein
Journal:  Immunol Today       Date:  2000-02

2.  Codon 72 polymorphism of the TP53 gene.

Authors:  S Ara; P S Lee; M F Hansen; H Saya
Journal:  Nucleic Acids Res       Date:  1990-08-25       Impact factor: 16.971

3.  AccII polymorphism of the p53 gene.

Authors:  O de la Calle-Martín; V Fabregat; M Romero; J Soler; J Vives; J Yagüe
Journal:  Nucleic Acids Res       Date:  1990-08-25       Impact factor: 16.971

4.  Anchorage-independent growth of synoviocytes from arthritic and normal joints. Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids.

Authors:  R Lafyatis; E F Remmers; A B Roberts; D E Yocum; M B Sporn; R L Wilder
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

5.  Mutations of the p53 tumour suppressor gene in erosive rheumatoid synovial tissue.

Authors:  T Rème; A Travaglio; E Gueydon; L Adla; C Jorgensen; J Sany
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

6.  Histomorphological basis of articular cartilage destruction in rheumatoid arthritis.

Authors:  H G Fassbender
Journal:  Coll Relat Res       Date:  1983-03

7.  Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.

Authors:  G Keyszer; I Lambiri; R Nagel; C Keysser; M Keysser; E Gromnica-Ihle; J Franz; G R Burmester; K Jung
Journal:  J Rheumatol       Date:  1999-02       Impact factor: 4.666

8.  p53 codon 72 polymorphism and risk of cervical cancer in UK.

Authors:  A N Rosenthal; A Ryan; R M Al-Jehani; A Storey; C A Harwood; I J Jacobs
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Survival of rheumatoid synovium implanted into nude mice.

Authors:  C E Brinckerhoff; E D Harris
Journal:  Am J Pathol       Date:  1981-06       Impact factor: 4.307

10.  Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population.

Authors:  S Olschwang; P Laurent-Puig; A Vassal; R J Salmon; G Thomas
Journal:  Hum Genet       Date:  1991-02       Impact factor: 4.132

View more
  2 in total

1.  Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case-control study.

Authors:  Christopher Butt; Lynette Peddle; Celia Greenwood; Sean Hamilton; Dafna Gladman; Proton Rahman
Journal:  Arthritis Res Ther       Date:  2006-01-03       Impact factor: 5.156

Review 2.  Polymorphism of genes and implantation failure.

Authors:  Majid Mojarrad; Mohammad Hassanzadeh-Nazarabadi; Niaiesh Tafazoli
Journal:  Int J Mol Cell Med       Date:  2013
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.